Biodesix, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +12.9% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.86 | $-0.71 | +17.4% | Beat | |
| Q1 FY26 | $-1.26 | $-0.81 | +35.7% | Beat | |
| Q4 FY25 | $-1.05 | $-0.49 | +53.3% | Beat | Q4 FY25 call |
| Q3 FY25 | $-1.60 | $-1.16 | +27.5% | Beat | |
| Q2 FY25 | $-0.07 | $-0.08 | -14.3% | Miss | |
| Q1 FY25 | $-0.08 | $-0.08 | +0.0% | Beat | |
| Q4 FY24 | $-0.07 | $-0.06 | +14.3% | Beat | |
| Q3 FY24 | $-0.08 | $-0.07 | +12.5% | Beat | |
| Q2 FY24 | $-0.09 | $-0.08 | +11.1% | Beat | |
| Q1 FY24 | $-0.15 | $-0.14 | +6.7% | Beat | |
| Q4 FY23 | $-0.11 | $-0.10 | +9.1% | Beat | |
| Q3 FY23 | $-0.15 | $-0.12 | +20.0% | Beat |
Back to BDSX overview · BDSX holders · BDSX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.